Low molecular weight activated protein C inhibitors as a potential treatment for hemophilic disorders

Journal of Medicinal Chemistry

Volumn 49, Issue 17, 2006, Pages 5047-5050

  De Nanteuil, Guillaume ^a   Gloanec, Philippe ^a   Béguin, Suzette ^a   Giesen, Peter L A ^a   Hemker, H Coenraad ^a   Mennecier, Philippe ^b   Rupin, Alain ^b   Verbeuren, Tony J ^b  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ACTIVATED PROTEIN C INHIBITOR; ANTICOAGULANT AGENT; BENZAMIDINE DERIVATIVE; BLOOD CLOTTING FACTOR 8A; PROCOAGULANT; PROTEINASE INHIBITOR; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; BLEEDING TENDENCY; ENZYME ACTIVITY; HEMARTHROSIS; HEMOPHILIA A; HUMAN; HYDROGENOLYSIS; PROTHROMBIN TIME; TISSUE DEGENERATION; VIRUS INACTIVATION;

BENZAMIDINES; FACTOR VIIIA; HEMOPHILIA A; HEMORRHAGE; HUMANS; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; PROTEIN C; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN;

EID: 33747501427     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0606950     Document Type: Article

References (10)

1. Klinge, J.; Ananyeva, N. M.; Hauser, C. A. E.; Saenko, E. L. Hemophilia A. From Basic Science to Clinical Practice. Semin. Thromb. Hemostasis 2002, 28, 309-321.
2. Bishop, P.; Lawson, J. Recombinant Biologies for Treatment of Bleeding Disorders. Nat. Rev. Drug Discovery 2004, 3, 684-694.
3. Kraus, M. The Anticoagulant Potential of the Protein C System in Hereditary and Acquired Thrombophilia: Pathomechanisms and New Tools for Assessing Its Clinical Relevance. Semin. Thromb. Hemostasis 1998, 24, 337-354.
4. Butenas, S.; Mann, K. Peptidomimetics Containing 6-Peptidylamino-1- Naphthalenesulfonamide Moieties. World Patent WO 98/22125, 1998.
5. 50 value with that obtained against thrombin in the presence of its natural substrate, fibrinogen (Enzyme Research Laboratories).
6. Lila, C.; Gloanec, P.; Cadet, L.; Hervé, Y.; Fournier, J.; Leborgne, F.; Verbeuren, T. J.; De Nanteuil, G. Large Scale Preparation of Protected 4-Aminomethylbenzamidine. Application to the Synthesis of the Thrombin Inhibitor Melagatran. Synth. Commun. 1998, 28, 4419-4429.
7. Hemker, H. C.; Giesen, P.; Al Dieri, R.; Regnault, V.; de Smedt, E.; Wagenvoord, R.; Lecompte, T.; Béguin, S. The Calibrated Automated Thrombogram (CAT): A Universal Routine Test for Hyper and Hypocoagulability. Pathophysiol. Haemostasis Thromb. 2002, 32, 249-253.
8. Hemker, H. C.; Giesen, P.; Al Dieri, R.; Regnault, V.; de Smedt, E.; Wagenvoord, R.; Lecompte, T.; Béguin, S. Calibrated Automated Thrombin Generation Measurement in Clotting Plasma. Pathophysiol. Haemostasis Thromb. 2003, 33, 4-15.
9. Gustafsson, D.; Nyström, J.-E.; Carlsson, S.; Bredberg; U.; Eriksson, U.; Gyzander, E.; Elg, M.; Antonsson, T.; Hoffmann, K.-J.; Ungell, A.-L.; Sörensen, H.; Någård, S.; Abrahamsson, A.; Bylund, R. The Direct Thrombin Inhibitor Melagatran and Its Oral Prodrug H 376/95: Intestinal Absorption Properties, Biochemical and Pharmacodynamic Effects. Thromb. Res. 2001, 101, 171-181.
10. Hauel, N. H.; Nar, H.; Priepke, H.; Ries, U.; Stassen, J.-M.; Wienen, W. Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors. J. Med. Chem. 2002, 45, 1757-1766.